Lactylation, a newly discovered post-translational modification, has been reported to be involved in various physiological and pathological processes. Recent studies have found that lactylation is potentially linked to the pathological processes and repair mechanisms of ischemic stroke. This article explores the impact and role of lactylation after the occurrence of ischemic stroke on neuroinflammation, energy metabolism regulation, oxidative stress, signaling pathway modulation, and angiogenesis. It may serve as a bridge connecting lactylation and ischemic stroke, offering insights and guidance for future research and clinical strategies in ischemic stroke.

Lactylation, a newly discovered post-translational modification, has been reported to be involved in various physiological and pathological processes. Recent studies have found that lactylation is potentially linked to the pathological processes and repair mechanisms of ischemic stroke. This article explores the impact and role of lactylation after the occurrence of ischemic stroke on neuroinflammation, energy metabolism regulation, oxidative stress, signaling pathway modulation, and angiogenesis. It may serve as a bridge connecting lactylation and ischemic stroke, offering insights and guidance for future research and clinical strategies in ischemic stroke.

Ischemic stroke has a high rate of disability and mortality and is often accompanied by white matter injury(WMI).WMI patients often have cognitive disorders,emotional disorders,sensorimotor disorders,urinary incontinence and other symptoms,which seriously affect daily life.WMI can be detected early through imaging techniques,but there is a lack of appropriate intervention and specific treatment.Studying the pathological mechanism of WMI after ischemic stroke is helpful to prevent the occurrence of WMI,delay its progression,and contribute to the development of effective drugs or specific treatments.This article reviewed the research progress of WMI mechanism after ischemic stroke in order to provide scientific basis for clinical prevention and treatment.

Objective:To analyze the changes in the prevalence and disability burden of mental disorders in the Chinese population from 1990 to 2019 and to provide a reference for reducing the health hazards of mental disorders.Methods:Based on the results of the Global Burden of Disease Study 2019 (GBD 2019)in China, the burden of mental disorders and disabilities in different age, gender, and provinces of the Chinese population in 2019 was analyzed. The changes in prevalence and years of life lived with disability(YLDs) of mental disorders between 1990 and 2019 were compared.Results:In 2019, the prevalence rate of mental disorders in the 50-69 age group in China was the highest (13.2%, 48.53 million patients), and the 0-14 age group was the lowest (7.3%, 16.456 million patients); the overall number of YLDs in women was higher than that in men (10.910/9.382 million person-years). In 2019, the number of patients with depressive disorders, anxiety disorders, and schizophrenia were 50.056 million, 47.842 million, and 5.499 million, respectively. The standardized prevalence of the three disorders was 2.7%, 3.2%, and 0.3%, respectively. Compared with 1990, the standardized prevalence of depressive disorders and anxiety disorders decreased by 9.1% and 9.8%, respectively, and the standardized prevalence rate of schizophrenia increased by 3.1%. In 2019, the top three provinces with standardized prevalence of mental disorders in China were Hunan (12.2%), Gansu (12.1%), and Ningxia (11.8%), and the number of people with mental disorders in these three provinces 8.901 million, 3.364 million, and 873 000, respectively. Three provinces with the top standardized YLDs rate were Shandong (1 470.0/10 5), Gansu (1 415.6/10 5), and Hunan (1 399.3/10 5). Conclusion:Mental disorders are essential disease threatening the Chinese population's physical and mental health.In 2019, the disability burden of mental disorders in China remained high. The burden of mental disorders and disabilities in women is more serious. Early intervention measures should be taken to reduce the disability burden of mental disorders.

Objective:To analyze the changes in the prevalence and disability burden of mental disorders in the Chinese population from 1990 to 2019 and to provide a reference for reducing the health hazards of mental disorders.Methods:Based on the results of the Global Burden of Disease Study 2019 (GBD 2019)in China, the burden of mental disorders and disabilities in different age, gender, and provinces of the Chinese population in 2019 was analyzed. The changes in prevalence and years of life lived with disability(YLDs) of mental disorders between 1990 and 2019 were compared.Results:In 2019, the prevalence rate of mental disorders in the 50-69 age group in China was the highest (13.2%, 48.53 million patients), and the 0-14 age group was the lowest (7.3%, 16.456 million patients); the overall number of YLDs in women was higher than that in men (10.910/9.382 million person-years). In 2019, the number of patients with depressive disorders, anxiety disorders, and schizophrenia were 50.056 million, 47.842 million, and 5.499 million, respectively. The standardized prevalence of the three disorders was 2.7%, 3.2%, and 0.3%, respectively. Compared with 1990, the standardized prevalence of depressive disorders and anxiety disorders decreased by 9.1% and 9.8%, respectively, and the standardized prevalence rate of schizophrenia increased by 3.1%. In 2019, the top three provinces with standardized prevalence of mental disorders in China were Hunan (12.2%), Gansu (12.1%), and Ningxia (11.8%), and the number of people with mental disorders in these three provinces 8.901 million, 3.364 million, and 873 000, respectively. Three provinces with the top standardized YLDs rate were Shandong (1 470.0/10 5), Gansu (1 415.6/10 5), and Hunan (1 399.3/10 5). Conclusion:Mental disorders are essential disease threatening the Chinese population's physical and mental health.In 2019, the disability burden of mental disorders in China remained high. The burden of mental disorders and disabilities in women is more serious. Early intervention measures should be taken to reduce the disability burden of mental disorders.

OBJECTIVE： To establish UPLC-Q- TOF-MS/MS fingerprint of Fritillaria thunbergii ， and to define its anti-inflammatory quality markers. METHODS ：The determination was performed on Eclipse Plus C 18 column with mobile phase consisted of methanol- 0.1％ formic acid solution （gradient elution ）at the flow rate of 0.4 mL/min. The column temperature was set at 30 ℃，and injection volume was 2 µL. The electrospray ion source was used to scan in the range of m/z 50-1 200 with positive and negative ion detection mode. UPLC-Q-TOF-MS/MS fingerprints of 10 batches of F. thunbergii from different habitats were established by using the Similarity Evaluation System of TCM Chromatographic Fingerprints （2004A edition ）. With ear swelling degree，the serum levels of MDA and NO as anti-inflammatory indexes ，the correlation between the relative area of common peaks in fingerprint and the anti-inflammatory indexes was analyzed by using bivariate correlation analysis and grey correlation analysis ， and the quality markers were screened and identified. RESULTS ：In positive and negative ion mode ，10 batches of F. thunbergii had 26 peaks and 10 peaks. Based on bivariate correlation analysis and grey correlation analysis ，nine quality markers related to anti-inflammatory effect were found ，which were identified as peiminine ，peimine，cyclobalamine，daucidin，polyphyllin Ⅴ， bitumen podophyllotoxin ，phytosterol，ent-kaur-15-en-17-ol，ent-17-norkauran-16-one. CONCLUSIONS ：Established UPLC-Q- TOF-MS/MS fingerprint can be used to evaluate the quality of F. thunbergii ；peiminine，peimine and cyclobalamine and so on may be the quality markers of anti-inflammatory effect of F. thunbergii .

To investigate the effect of hSCGF-alpha on human Umbilical Cord Mesenchymal Stem Cells (hUCMSCs), we obtained hSCGF-alpha using genetic engineering, hSCGF-alpha gene was amplified from hUCMSCs cDNA using two-step PCR and was inserted into pET-28a(+) plasmid vector. Induced by IPTG at 20 degrees Celsius for 24 h, the fusion protein expressed in E. coli BL21 (DE3) was mainly existing in soluble form. The recombinant hSCGF-a was purified using NI-NTA affinity chromatography and the purity was up to 90%. The colony forming test revealed that combined use hSCGF-alpha and rmGM-CSF (recombinant murine GM-colony stimulating factor, rmGM-CSF) had granulocyte/macrophage (GM) promoting effects on murine bone marrow GM progenitor. In addition, the results indicated that hSCGF-alpha and rhGM-CSF had stimulatory effect on hUCMSCs and their synergetic effect was the strongest.
Cell Proliferation ; drug effects ; Cells, Cultured ; Cloning, Molecular ; Drug Synergism ; Escherichia coli ; genetics ; metabolism ; Granulocyte-Macrophage Colony-Stimulating Factor ; pharmacology ; Humans ; Mesenchymal Stromal Cells ; cytology ; metabolism ; Recombinant Fusion Proteins ; biosynthesis ; genetics ; pharmacology ; Stem Cell Factor ; biosynthesis ; genetics ; Umbilical Cord ; cytology